Related Experiment Video
Updated: Oct 19, 2025
09:12
A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
Published on: June 15, 2018
10.2K
Association Between Immunosuppressive Therapy and Outcome of Clostridioides difficile Infection: Systematic Review
Yiting Li1,2, Haifeng Cai3, Daniel A Sussman4
1Department of Internal Medicine, Saint Francis Medical Center, Trenton, NJ, USA.
Digestive Diseases and Sciences
|September 23, 2021
Summary
Immunosuppressive therapy increases the risk of complicated outcomes in patients with Clostridioides difficile infection (CDI). This therapy is linked to higher rates of death and severe complications in CDI patients, highlighting a significant association.
Area of Science:
- Infectious Diseases
- Clinical Medicine
- Pharmacology
Background:
- Clostridioides difficile infection (CDI) patients often have comorbidities requiring immunosuppressive therapy.
- Limited data exist on the impact of immunosuppressive therapy on CDI outcomes.
Purpose of the Study:
- To determine the association between immunosuppressive therapy and outcomes in adult patients with CDI.
Main Methods:
- Systematic review and meta-analysis of studies from PubMed, Embase, and Cochrane Library up to February 2021.
- Included studies compared adult CDI patients receiving immunosuppressive therapy versus those who did not.
- Primary outcome was complicated CDI (death, surgery, shock, ICU admission); pooled odds ratios (ORs) were calculated.
Main Results:
- Twenty-two studies with 5759 patients were analyzed.
- Immunosuppressive therapy was significantly associated with complicated CDI (OR 1.61) and death (OR 1.73).
- Corticosteroids showed a significant association with complicated CDI (OR 1.73).
Conclusions:
- Immunosuppressive therapy is a significant risk factor for complicated outcomes in CDI.
- Findings highlight the need to consider immunosuppressive therapy's role in CDI management.
- Subgroup analyses indicated study quality and confounder adjustment influence results.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
287
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
287
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
240
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
240
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
259
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
259
01:29Inflammatory Bowel Disease IV: Pharmacological Management
242
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
242
01:29Pulmonary Tuberculosis I
419
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
419
01:29Drugs for Treatment of Ulcerative Colitis in IBD
270
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
270